Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

In 2026, investors face a decision between two healthcare stocks: Axsome Therapeutics (AXSM) and Moderna (MRNA). Each company presents distinct opportunities and challenges in the rapidly evolving biopharmaceutical industry. Axsome Therapeutics specializes in treating complex central nervous system (CNS) conditions, having developed a portfolio of approved drugs.

Its current lineup includes AUVELITY for depression, SUNOSI for narcolepsy, and SYMBRAVO. The company has experienced rapid commercial growth, employing nearly 925 individuals by early 2026. Axsome relies on its own commercial efforts within the United States, while also leveraging partnerships such as its licensing agreement with Pharmanovia to expand its reach into Europe, the Middle East, and North Africa.

Moderna, on the other hand, is harnessing its proprietary mRNA technology to transcend the pandemic and target a broader spectrum of viruses and cancers. This biotechnology firm is leveraging its established mRNA platform to develop innovative therapies beyond the COVID-19 vaccine. While Moderna's commercial footprint is less mature compared to Axsome, the company's technology holds the potential for groundbreaking treatments across various diseases.

Both Axsome and Moderna operate in a high-risk, high-reward environment, as they navigate the challenges and uncertainties inherent in drug development and commercialization. However, the distinct strategic paths of each company—Axsome focusing on CNS conditions and Moderna on broad therapeutic applications—offer investors different avenues for potential growth in the healthcare sector by 2026.